Gregory Behar Net Worth

Gregory Behar biography

Gregory Behar serves as Independent Director of the Company. Mr. Behar has also served as Chief Executive Officer of Nestlé Health Science S.A., a health sciences company, since October 2014. He currently serves on the board of directors of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) and Seres Therapeutics, Inc. (Nasdaq: MCRB). Mr. Behar holds an M.B.A. from INSEAD in France, a M.S. in mechanical engineering and manufacturing from EPFL in Switzerland, and a B.S. in mechanical engineering from the University of California, Los Angeles.

What is the salary of Gregory Behar?

As the Independent Director of Axcella Health Inc, the total compensation of Gregory Behar at Axcella Health Inc is $131,426. There are 8 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of $3,911,720.

How old is Gregory Behar?

Gregory Behar is 50, he's been the Independent Director of Axcella Health Inc since 2016. There are 13 older and 4 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.

What's Gregory Behar's mailing address?

Gregory's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa..., and Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.

What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.

Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include:

• Shreeram Aradhye,
  Executive Vice President, Chief Development Officer
• Manu Chakravarthy,
  Senior Vice President, Chief Medical Officer
• William Hinshaw,
  President, Chief Executive Officer, Director
• David Epstein,
  Chairman of the Board
• William R. Hinshaw Jr.,
  Pres, CEO & Director
• Laurent Chardonnet,
  Consultant
• William Baird,
  Independent Director
• Catherine Sohn,
  Independent Director
• Gary Pisano,
  Independent Director
• Gregory Behar,
  Independent Director
• Cristina Rondinone,
  Independent Director
• Stephen Hoge,
  Independent Director
• Stephen Mitchener,
  Senior Vice President, Chief Business Officer
• Paul Fehlner,
  Senior Vice President, Chief Intellectual Property Officer
• Heidy King-Jones,
  Senior Vice President of Legal, General Counsel
• Tony Tramontin,
  Senior Vice President of Research and Development , Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer, Senior Vice President
• Karim Azer Ph.D.,
  VP of Systems Biology & Discovery
• Dr. Margaret Koziel M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Alison D. Schecter M.D.,
  Pres of R&D
• Dr. Larry Bell,
  Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
• Virginia R. Dean,
  Sr. VP & Chief People Officer
• Dr. Paul Fehlner J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Jason Fredette,
  VP of Investor Relations & Corp. Communications
• Health Science Us Holdings,...,
  
• Michael Rosenblatt,
  Director
• David A Berry,
  Director
• Ventures Fund Iv General Pa...,
  
• Paul J Sekhri,
  Director
• Ventures Fund Iv General Pa...,
  
• Des Produits Nestle S.A.Nes...,
  
• Alison D. Schecter,
  President - Research & Dev.
• Virginia R Dean,
  SVP, Chief People Officer
• Margaret Koziel,
  Chief Medical Officer
• Ventures Fund Iv General Pa...,
  
• Robert Crane,
  Chief Financial Officer
• Torben Straight Nissen,
  Director
• Robert L. Rosiello,
  Director